KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat.

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

CUHK researchers say drug D3S-001 can treat non-small cell lung, colorectal and pancreatic cancers triggered by gene mutation ...

Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

KRAS and NRAS are members of the RAS family of genes, which encode proteins that regulate cell growth and division through signaling pathways. Mutations in these genes disrupt normal signaling, ...

Silexion Therapeutics Corp has completed a significant preclinical study evaluating its RNA interference therapeutic candidate, SIL204, for various KRAS-driven cancers, including colorectal and ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional ...

Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have described GTPase KRAS (G12D mutant) and/or KRAS (G12V mutant) inhibitors reported to be useful for the ...